Výsledky vyhledávání - "Surya Vangala"

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

Autor: Mark N Stein, Lawrence Fong, Ronald Tutrone, Anthony Mega, Elaine T Lam, Megan Parsi, Surya Vangala, Andres A Gutierrez, Naomi B Haas

Publikováno v: The Oncologist. 27:453-461

Background ADXS31-142 is an attenuated Listeria monocytogenes-based immunotherapy targeting prostate-specific antigen (PSA), being evaluated as monotherapy and combined with pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC). P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5e943ac3fd1fa1f0d718cd1af149a4
https://doi.org/10.1093/oncolo/oyac048

Zobrazit plný text záznamu

Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab

Autor: Aaron E. Lisberg, Jonathan W. Goldman, Balazs Halmos, Gregory James Gerstner, Neil Morganstein, Charles Michael Farber, Kyoung A Viola Lee, Lydia ML Holtgrewe, Casey Codd, Angelina Bisconte, Theodore Foss, Surya Vangala, Megan Parsi, Andres A. Gutierrez, Suresh S. Ramalingam

Publikováno v: Journal of Clinical Oncology. 40:9042-9042

9042 Background: The administration of a lung cancer-specific immunotherapy with 22 tumor-associated antigens (ADXS-503, A503), has been evaluated as an add-on therapy for patients (pts) with metastatic non-small-cell lung cancer (NSCLC) who have pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55e282762d147bb5cd35b7a62d70100e
https://doi.org/10.1200/jco.2022.40.16_suppl.9042

Zobrazit plný text záznamu

360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)

Autor: Victor Kabala, Gregory James Gerstner, Suresh S. Ramalingam, Jonathan H. Goldman, Dinesh Simkhada, Megan Parsi, Missak Haigentz, Surya Vangala, Thomas E. Stinchcombe, Andres A. Gutierrez

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background ADXS-503 (A503) is an off-the-shelf, attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit potent T cell responses against 22 tumor antigens commonly found in NSCLC (i.e., 11 hotspot mutations and 11 tumor-asso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43814ef2476ca28c9e5bf8f35e7e91cb
https://doaj.org/article/3c83edd4098443779669a783f3e8302a

Zobrazit plný text záznamu

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Autor: Megan Parsi, Jonathan W. Goldman, Cristiane Metran, Victor Kabala, Dinesh Simkhada, Missak Haigentz, Suresh S. Ramalingam, Gregory James Gerstner, Surya Vangala, Andres A. Gutierrez, Balazs Halmos, Neil Morganstein

Publikováno v: Journal of Clinical Oncology. 39:2616-2616

2616 Background: ADXS-503 (A503) is an off-the-shelf, attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit potent T cell responses against 22 tumor antigens commonly found in NSCLC (i.e., 11 hotspot mutations and 11 tumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bc680cfaa78ce74bc10469afd838f24
https://doi.org/10.1200/jco.2021.39.15_suppl.2616

Zobrazit plný text záznamu

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Autor: Missak Haigentz, Surya Vangala, Tuhina Prasad, Jonathan W. Goldman, Megan Parsi, Victor Kabala, John W. Heyburn, Suresh Ramalingam, Andres A. Gutierrez, Tom Stinchcombe, Gregory James Gerstner

Publikováno v: Journal of Clinical Oncology. 38:e21682-e21682

e21682 Background: ADXS-503 (A503) is an off-the-shelf, attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit potent T cell responses against 22 tumor antigens commonly found in NSCLC (i.e., 11 hotspot mutations and 11 tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3eaa740f4c528ee880de673ffbbeb84a
https://doi.org/10.1200/jco.2020.38.15_suppl.e21682

Zobrazit plný text záznamu

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Autor: John W. Heyburn, Andres A. Gutierrez, Naomi B. Haas, Megan Parsi, Lawrence Fong, Mark N. Stein, Surya Vangala, Anthony Mega, Elaine T. Lam

Publikováno v: Journal of Clinical Oncology. 38:126-126

126 Background: ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy targeting prostate-specific antigen (PSA), is currently being evaluated in combination with pembrolizumab as a treatment for progressive metastatic castration-resistan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea5f4735b762abfd3df10a1d4427caef
https://doi.org/10.1200/jco.2020.38.6_suppl.126

Zobrazit plný text záznamu

Abstract CT098: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients

Autor: Lawrence Fong, Elaine T. Lam, Naomi B. Haas, Sandy Hayes, Ronald F. Tutrone, Anthony Mega, Justin G. Dennie, Andres Gutierrez, Mark N. Stein, Robert Petit, Surya Vangala

Publikováno v: Cancer Research. 79:CT098-CT098

Background: ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy targeting prostate-specific antigen (PSA), is currently being evaluated as a treatment for progressive metastatic castration-resistant prostate cancer (mCRPC) in the Phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bba9868d01e585cc13c3d16c1257e210
https://doi.org/10.1158/1538-7445.am2019-ct098

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání